Arca
Skip to content
Tools
Tools

RARA: Retinoic acid receptor alpha

Receptor for retinoic acid.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on RARA, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2

Approved1

  • Tamibarotene

Phase 30

    Phase 21

    • NRX195183

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      TamibaroteneApprovedRege Nephro Co., Ltd.Small moleculeAgonistRetinoic acid receptor alpha agonist3
      NRX195183Phase 2—Small moleculeAgonistRetinoic acid receptor alpha agonist0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 3 in all, from ClinicalTrials.gov.
      The Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial)TamibarotenePhase 2RecruitingNagoya UniversityOct 2, 2026
      Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial CarcinomaTamibarotenePhase 2RecruitingNagoya UniversityMay 21, 2025
      Study of Tamibarotene in Patients With ADPKDTamibarotenePhase 2Active, not recruitingRege Nephro Co., Ltd.Mar 4, 2024

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Psoriasis vulgaris0.57
      • Hyperpigmentation of the skin0.54
      • Freckles0.54
      • Neoplasm0.51
      • Kaposi's sarcoma0.47
      • Atopic eczema0.46
      • Neurodegenerative disease0.44

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2055, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P10276, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.